Akebia Therapeutics (AKBA) Liabilities and Shareholders Equity (2013 - 2026)

Akebia Therapeutics (AKBA) has 14 years of Liabilities and Shareholders Equity data on file, last reported at $362.5 million in Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 16.87% year-over-year to $362.5 million in Q1 2026; TTM through Mar 2026 was $1.4 billion, a 51.2% increase from a year earlier, with the FY2025 full-year figure at $376.6 million, up 70.65% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $362.5 million, down from $376.6 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for AKBA reached as high as $541.8 million in Q1 2022 and fell as low as $207.1 million in Q3 2024.
• Historically, Liabilities and Shareholders Equity has averaged $324.5 million across 5 years, with a median of $310.2 million in 2025.
• Across the five-year window, Liabilities and Shareholders Equity tumbled 52.12% in 2023 and jumped 75.8% in 2025, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $356.1 million in 2022, then tumbled by 32.12% to $241.7 million in 2023, then fell by 8.7% to $220.7 million in 2024, then surged by 70.65% to $376.6 million in 2025, then decreased by 3.73% to $362.5 million in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $362.5 million in Q1 2026, $376.6 million in Q4 2025, and $364.2 million in Q3 2025.